The artificial urinary sphincter (AUS) is the standard treatment of male urinary incontinence (SUI) and has the longest efficacy record. However, revision rates are reported in up to a third of the cases. Revision and explanation rates dues to urethral atrophy and cuff erosion vary considerably among published studies. In addition to general risk factors, this may be attributed to high occlusion pressures. The aim is to determine the safety and efficacy of a novel AUS.
INTRODUCTION AND OBJECTIVES:
The artificial urinary sphincter (AUS) is the standard treatment of male urinary incontinence (SUI) and has the longest efficacy record. However, revision rates are reported in up to a third of the cases. Revision and explanation rates dues to urethral atrophy and cuff erosion vary considerably among published studies. In addition to general risk factors, this may be attributed to high occlusion pressures. The aim is to determine the safety and efficacy of a novel AUS.
METHODS: VICTO is a single unit pre-connected adjustable device with an occluding cuff (OC), a pressure regulating balloon and a scrotal pump with a self-sealing port for pressure adjustment. VICTOplus has additionally a stress relief balloon to transmit transient intraabdominal pressure changes to the OC. The regulating pressure is adjustable in the range 0-100 cmH2O and can be altered at any time after implantation by injection or removal of fluid. In the time between 12/2016 and 10/2018 the device was indicated in 52 patients with SUI after prostate surgery (prostatectomy n[45; transurethral prostate resection n[4; traumata[3) . We included the data from 45 patients (VICTO n[18, VICTOplus n[27) with a mean follow-up time of 10.1 months (range 1.2-21.1). Patients with more than 2 prior incontinence surgeries were excluded (n[2) and 5 systems were not activated at the time of the data collection. We used a telephone questionnaire to collect postoperative data as daily pad use and satisfaction rate. Average age at time of implantation was 69.5 (AE 9.7) years. There were between 1 to 5 (IQR[1.5, M[1) readjustment needed to achieve a sufficient result.
RESULTS: In all 45 cases the device was easily implanted without any intraoperative complications. One patient with persistent incontinence after VICTO-Implantation required a smaller OC. The pad per day usage improved from 6.4 (AE3.5) to 1.6 (AE1) and the continence rate (max. 1p/d) was 53.3%. The overall satisfaction was 83.8% and 88.6% would undergo the same operation again. Only 4 patients had an improvement less than 50%, all of them are not fully activated yet and may improve more with future adjustments.
CONCLUSIONS: The device provides adjustability in regulating pressure in situ. In our cohort of 45 patients, 91.1% had at least an improvement of 50% and these short results are promising and challenge prior AUS series. Adjusting the system pressure to the lowest level providing continence may reduce the long-term rate of erosions and "subcuff atrophy", however such data are not yet available. shown that men with low serum testosterone appear to have a higher risk of artificial urinary sphincter (AUS) cuff erosion. However, the urethral sequelae of androgen deprivation therapy (ADT) among AUS patients have not been well studied. We hypothesized that men on ADT for advanced prostate cancer may be at increased risk for urethral atrophy and AUS complications.
METHODS: In our large AUS database of cases performed by a single surgeon 2007-2018 at a tertiary urban medical center, we identified two group of men: those who had received ADT (typically with radiation) and those with known normal serum testosterone (T) levels without a history of ADT or radiation. Demographic and outcome data were collected and analyzed to determine trends in cuff sizes used in these men and rates of urethral erosion. Use of a 3.5 cm AUS cuff was defined as a surrogate for urethral atrophy and compared between groups.
RESULTS: From our database of 643 AUS cases during the study interval, we identified 67 (10.4%) who had been on ADT and 32 (5%) with normal T and no history of prior ADT or radiation. In these groups, 17 (26.2%) men on ADT developed AUS cuff erosion compared with 1 (3.7%) in the normal T group, which was significant on univariate analysis (p[0.02). A 3.5 cm AUS cuff was utilized more commonly among the ADT group (32/67, 48.5%) compared with the control group (9/32, 28.1%, p[0.08). Among men with 3.5 cm cuffs, the rates of urethral erosion were significantly higher among men who had been on ADT (31.2%) compared with the control group (11.1%, p[0.04) .
CONCLUSIONS: Men with a history of ADT appear to have a greater likelihood of urethral atrophy, as manifested by increased use of 3.5 cm AUS cuff. This further supports the adverse relationship between hypogonadism and urethral homeostasis, which may contribute to increased rates of AUS cuff erosion. AUS patients receiving ADT for advanced prostate cancer should be counseled appropriately regarding this elevated risk. 
